APPL1 Potentiates Insulin-Mediated Inhibition of Hepatic Glucose Production and Alleviates Diabetes via Akt Activation in Mice  by Cheng, Kenneth K.Y. et al.
Cell Metabolism
ArticleAPPL1 Potentiates Insulin-Mediated Inhibition
of Hepatic Glucose Production and Alleviates
Diabetes via Akt Activation in Mice
Kenneth K.Y. Cheng,1,2 Miguel A. Iglesias,3 Karen S.L. Lam,1,2 Yu Wang,2,4 Gary Sweeney,5 Weidong Zhu,1,2
Paul M. Vanhoutte,2,4 Edward W. Kraegen,3,* and Aimin Xu1,2,4,*
1Department of Medicine
2Research Center of Heart, Brain, Hormone and Healthy Aging
The University of Hong Kong, Hong Kong
3Garvan Institute of Medical Research and School of Medical Sciences, University of NSW, Sydney, NSW 2010, Australia
4Department of Pharmacology, The University of Hong Kong, Hong Kong
5Department of Biology, York University, Toronto, ON M3J 1P3, Canada
*Correspondence: e.kraegen@garvan.org.au (E.W.K.), amxu@hkucc.hku.hk (A.X.)
DOI 10.1016/j.cmet.2009.03.013SUMMARY
Hepatic insulin resistance is the major contributor to
fasting hyperglycemia in type 2 diabetes. Here we
report that the endosomal adaptor protein APPL1
increases hepatic insulin sensitivity by potentiating
insulin-mediated suppression of the gluconeogenic
program. Insulin-stimulated activation of Akt and
suppression of gluconeogenesis in hepatocytes are
enhanced by APPL1 overexpression, but are attenu-
ated by APPL1 knockdown. APPL1 interacts with Akt
and blocks the association of Akt with its endoge-
nous inhibitor tribble 3 (TRB3) through direct compe-
tition, thereby promoting Akt translocation to the
plasma membrane and the endosomes for further
activation. In db/db diabetic mice, the blockage of
the augmented interaction between Akt and TRB3
by hepatic overexpression of APPL1 is accompanied
by a marked attenuation of hyperglycemia and
insulin resistance. These results suggest that the
potentiating effects of APPL1 on insulin-stimulated
suppression of hepatic glucose production are
attributed to its ability in counteracting the inhibition
of Akt activation by TRB3.
INTRODUCTION
The liver is the primary organ responsible for endogenous
glucose production, which is tightly controlled by various meta-
bolic and nutritional factors (Accili, 2004). In the fasted state,
hepatic glucose production (HGP) is enhanced by glucagon
to maintain euglycemia, thus ensuring that glucose-dependent
tissues such as the brain have access to an energy supply.
When blood glucose levels are elevated after nutrient ingestion,
HGP is suppressed by insulin (Barthel and Schmoll, 2003). The
inhibitory effect of insulin on HGP is mediated by activation of
Akt (also known as protein kinase B). Akt reduces the expres-
sion of the key gluconeogenic enzymes phosphoenolpyruvatecarboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase)
by suppressing the activity of FOXO1, a member of the fork-
head family of transcription factors (Accili, 2004; Nakae et al.,
2002). In the absence of insulin, FOXO1 is localized in the
nucleus, where it transactivates the two gluconeogenic genes.
Upon insulin stimulation, activated Akt phosphorylates FOXO1
at three conserved sites, inducing FOXO1 translocation to the
cytoplasm and thereby reducing its transcriptional activity. A
key role of the Akt/FOXO1 branch of insulin signaling in sup-
pressing HGP is highlighted by a recent study showing that
liver-specific depletion of FOXO1 results in a complete reversal
of diabetes in insulin receptor substrate (IRS) 1 and 2 knockout
mice (Dong et al., 2008). In addition, activated Akt also inhibits
the gluconeogenic program through a phosphorylation-depen-
dent inhibition of the peroxisome proliferator-activated receptor
g coactivator 1 a (PGC-1a) and TORC2, both of which act in
concert with FOXO1 in transactivating the gluconeogenic
genes (Dentin et al., 2007; Li et al., 2007b; Puigserver et al.,
2003).
Hepatic insulin resistance, which leads to excessive HGP, is
the major contributor to fasting hyperglycemia in patients with
type 2 diabetes mellitus (T2DM) (Biddinger and Kahn, 2006;
Magnusson et al., 1992). The central role of excessive HGP in
the pathogenesis of T2DM is underscored by the fact that current
antidiabetic drugs such as metformin decrease blood glucose
levels through inhibiting hepatic gluconeogenesis (Zhou et al.,
2001). Therefore, identification of novel molecules involved in
regulating the hepatic insulin signaling pathway leading to the
inhibition of glucose production might provide potential new
targets for novel therapeutic intervention in the treatment of
T2DM, a major health burden worldwide.
APPL1, an adaptor protein containing an NH2-terminal Bin/
Amphiphysin/Rvs (BAR) domain, a central pleckstrin homology
(PH) domain, and a COOH-terminal phosphotyrosine-binding
(PTB) domain (Hosch et al., 2006), was originally identified as
an interacting partner of Akt in a yeast two-hybrid assay using
Akt2 as a bait (Mitsuuchi et al., 1999). Subsequent studies
demonstrate that APPL1 binds to a number of cell-surface
receptors (TrkA [Lin et al., 2006; Varsano et al., 2006]; DCC
[Liu et al., 2002]), adiponectin (Cheng et al., 2007; Mao et al.,Cell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc. 417
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APPL1, TRB3, and Insulin-Evoked Akt SignalingFigure 1. Suppression of APPL1 Expression by siRNA Decreases Insulin-Evoked Activation of the Akt Signaling Pathway and Inhibits
the Cytoplasmic Translocation of FOXO1 in Rat Hepatocytes
Cells transduced with adenovirus encoding APPL1 siRNA (siAPPL1) or scrambled control at the concentration of 75 plaque-forming units (p.f.u.)/cell were treated
with insulin for various time periods.
(A) Total cell lysates were subjected to immunoblotting analysis using antibodies against total or phospho-Akt (Ser-473), total or phospho-G3K3b (Ser-9), or total
or phospho-FOXO1 (Ser-256), as indicated.
(B) The phosphorylation levels of Akt, GSK3b, and FOXO1 were quantified using scanning densitometry, and the results are expressed as fold changes relative
to non-insulin-treated control (time = 0 min).
(C) Nuclear (N) and cytoplasmic (C) fractions isolated from cells treated with 10 nM insulin for 0 and 30 min were analyzed by western blot to quantify the
subcellular distribution of FOXO1.
Error bars are ±SEM. **p < 0.01 (n = 4–5).2006), FSH (Nechamen et al., 2004) and intracellular signaling
molecules (small GTPase Rab5; Miaczynska et al., 2004),
GIPC (Varsano et al., 2006), and inositol 5-phosphatase (Erd-
mann et al., 2007), suggesting that APPL1 may act as
a common relay to coordinate diverse signaling cascades.
Notably, the interaction of APPL1 with adiponectin receptors
has recently been shown to be essential in mediating its
insulin-sensitizing actions in muscle (Mao et al., 2006) and
endothelial cells (Cheng et al., 2007). A more recent study on
zebrafish demonstrates that APPL1 not only plays an essential
role in Akt activation but also determines Akt substrate speci-
ficity (Schenck et al., 2008). In mammalian cells, APPL1 has
also been implicated in Akt activation by several extracellular
stimuli including androgen (Yang et al., 2003) and NGF-1 (Lin
et al., 2006). Furthermore, APPL1 is required for insulin-stimu-
lated translocation of GLUT4 from cytoplasm to plasma
membrane and glucose uptake in adipocytes and myotubes
(Saito et al., 2007).
Although the aforementioned in vitro findings suggest a poten-
tial role of APPL1 as an important player in the insulin-mediated
Akt signaling cascade, the physiological functions of APPL1 and
the underlying molecular mechanisms have not been explored.
In light of the fact that APPL1 is highly expressed in the liver
(Mao et al., 2006), we investigated the role of this protein in
insulin-mediated inhibition of HGP in both primary hepatocytes
and rodent models. In addition, we elucidated the molecular
basis whereby APPL1 potentiates insulin-evoked activation of
Akt and its downstream targets.418 Cell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc.RESULTS
APPL1 Potentiates Insulin-Evoked Akt Signaling
in Rat Hepatocytes
To investigate the role of APPL1 in regulating insulin sensitivity in
hepatocytes, we employed the adenoviral delivery system for
knockdown of this adaptor protein. The APPL1 protein level
was decreased by approximately 70% in primary rat hepato-
cytes infected with adenovirus that encodes a small hairpin
RNA (siRNA) specific to the APPL1 gene, compared with the
cells infected with adenovirus encoding a scrambled control
(Figure 1A). Knockdown of APPL1 expression attenuated
insulin-stimulated phosphorylation of Akt at Ser-473, and conse-
quently reduced the phosphorylation of FOXO1 and glycogen
synthase kinase 3b (GSK-3b) (Figures 1A and 1B). Subcellular
fractionation analysis showed that insulin stimulation prompted
the translocation of FOXO1 from the nucleus to the cytoplasm,
whereas this effect of insulin was attenuated in cells with a
reduced APPL1 expression (Figure 1C).
To further confirm the above findings, we also examined the
effect of APPL1 overexpression in mediating the hepatic actions
of insulin (see Figure S1 available online). Infection of rat hepato-
cytes with recombinant adenovirus encoding full-length human
APPL1 for 48 hr led to an approximately 2.5-fold increase in
APPL1 protein levels compared to that infected with adenovirus
encoding luciferase control. Overexpression of APPL1 markedly
increased the magnitude of insulin-evoked phosphorylation of
Akt and its two downstream targets (FOXO1 and GSK-3b),
Cell Metabolism
APPL1, TRB3, and Insulin-Evoked Akt SignalingFigure 2. The Suppressive Effects of Insulin on Glucose Production and Gluconeogenic Gene Expression Are Altered by APPL1 Knockdown
or Overexpression in Rat Hepatocytes
(A–F) Cells were transduced with adenovirus encoding APPL1-specific siRNA (siAPPL1) or scrambled control (A–C), or with adenovirus encoding APPL1
(adv-APPL1) or luciferase (adv-luc) control (D–F) at the concentration of 75 p.f.u./cell for 48 hr. The effects of insulin on cAMP/Dex-induced glucose production
were analyzed as described in Experimental Procedures. The mRNA expression of PEPCK andG6Pasewas quantified by real-time PCR and normalized against
18S RNA.
Error bars are ±SEM. *p < 0.05; **p < 0.01 (n = 4–6).although the phosphorylation of these proteins under the basal
condition were little affected.
APPL1 Enhances Insulin-Mediated Suppression
of Hepatic Glucose Production
Treatment of primary hepatocytes with N6,20-O-dibutyryladeno-
sine 30,50-cyclic monophosphate sodium salt (cAMP; 100 mM)
and dexamethasone (Dex; 500 nM) resulted in a 3.1-fold increase
in glucose production (Figure 2A). Knockdown of APPL1 expres-
sion did not affect glucose production under the basal condition
or under the stimulation with cAMP/Dex, but markedly attenu-
ated the suppressive effects of insulin on hepatic glucose
production. Insulin at the concentrations of 2 and 10 nM inhibited
cAMP/Dex-induced glucose production by 33% ± 2% and
58% ± 5%, respectively, in cells infected with a scrambled
control, compared to 14% ± 1% and 31% ± 4% reductions in
cells infected with APPL1-specific siRNA (n = 6, p < 0.05 for
both comparisons). In addition, siRNA-mediated reduction of
APPL1 expression attenuated the suppressive effects of insulin
on cAMP/Dex-induced expression of PEPCK and G6Pase, the
two key enzymes involved in gluconeogenesis (Figures 2B and2C). Conversely, overexpression of APPL1 enhanced the effect
of insulin on inhibiting hepatic glucose production and on sup-
pressing the expression of the two gluconeogenic genes (PEPCK
andG6Pase) inducedbycAMP/dexamethasone (Figures 2D–2F),
suggesting that APPL1 potentiates the hepatic actions of insulin
on inhibiting glucose production via Akt activation.
Hepatic Silencing of APPL1 Decreases Insulin
Sensitivity and Glucose Tolerance in Mice
To investigate the effects of APPL1 on hepatic insulin sensitivity
in vivo, we injected C57BL/6J mice with adenovirus encoding
APPL1-specific siRNA to reduce its expression in the liver.
Western blot analysis showed a time-dependent decrease in
APPL1 expression in the liver after injection with adenoviruses
(Figure 3A). On days 5 and 8 after adenoviral infection, the
protein abundance of APPL1 was decreased by approximately
79% and 65%, respectively, compared to the scrambled control
group. Afterward, the knockdown efficiency was gradually
diminished.
Knockdown of APPL1 in the liver did not affect food intake and
body weight gains (data not shown), but significantly increasedCell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc. 419
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APPL1, TRB3, and Insulin-Evoked Akt SignalingFigure 3. Knockdown of APPL1 Expression by siRNA Impairs the Hepatic Actions of Insulin and Induces Hyperglycemia in C57 Mice
Ten-week-old C57 male mice were treated with adenovirus encoding APPL1 siRNA (siAPPL1) or scrambled control by tail vein injection (2 3 109 p.f.u./mouse).
(A) Western blot analysis to detect protein levels of APPL1 in the liver tissue of mice at various days after adenoviral infection. The bar chart below the blot is
the quantitative analysis of APPL1 protein abundance.
(B) Fasting glucose levels at various days after adenoviral infection.
(C) Insulin tolerance test (ITT) on day 9.
(D) Phosphorylation of Akt and its two targets in response to acute insulin injection (0.5 IU insulin/kg body weight) on day 10. Data are expressed as fold changes
relative to the baseline control (time = 0 min).
(E) Glucose tolerance test (GTT) on day 6.
(F) Circulating levels of insulin at various time points during the glucose tolerance test on day 6.
(G) Pyruvate tolerance test (PTT) on day 7.
Error bars are ±SEM. *p < 0.05; **p < 0.01 (n = 5–7).plasma levels of fasting glucose (Figure 3B). The most profound
elevation of fasting glucose was detected on day 5, which was in
parallel with the greatest reduction in APPL1 expression. Insulin
tolerance test, conducted at day 9 after adenoviral injection,
showed significantly decreased insulin sensitivity in mice with
reduced APPL1 expression, as evidenced by a much greater
area under the glucose curve compared to scrambled control
(Figure 3C). These changes during APPL1 knockdown was
accompanied at amolecular level by decreased phosphorylation
of Akt and its two downstream targets GSK3b and FOXO1 in
response to acute intraperitoneal insulin injection (Figure 3D), a
finding consistent with the observation in isolated hepatocytes
(Figure 1).
Glucose tolerance test, conducted at day 6 after infusion with
recombinant adenoviruses, showed that knockdown of APPL1
expression in the liver caused a significant impairment in glucose
excursion after glucose challenge (Figure 3E). Noticeably, insulin
levels at both baseline and during glucose tolerance test were420 Cell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc.elevated in mice with reduced APPL1 expression in the liver
(Figure 4F). The effect of APPL1 knockdown on inducing glucose
intolerance was insignificant at day 13 (data not shown), perhaps
due to the decreased knockdown efficiency and/or the compen-
satory increase of circulating insulin, thus leading to an increased
glucose disposal in other insulin targets such as skeletal muscle
and adipocytes.
To determine the role of APPL1 in modulating gluconeogen-
esis in vivo, we also examined blood glucose levels in mice
following intraperitoneal injection of pyruvate in a separate set
of experiments (Figure 3G). In control mice, blood glucose
increased to a peak level at 60 min after pyruvate administration,
and decreased afterward. However, in micewith reduced APPL1
expression, blood glucose continued to rise at 90 min, and did
not significantly decrease until 120 min. Compared to the mice
infected with scrambled control, the glucose area after pyruvate
challenge was much greater in mice infected with adenovirus
encoding APPL1-specific siRNA.
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APPL1, TRB3, and Insulin-Evoked Akt SignalingFigure 4. Adenovirus-Mediated Expression of APPL1 Alleviates Diabetic Phenotype in db/db Obese Mice
(A) Immunoblot analysis to detect the protein levels of APPL1 in the liver tissue of db/db mice at day 16 after infection with adenovirus (Adv) encoding APPL1
or luciferase (luc) control (2 3 109 p.f.u./mouse).
(B) Fed and fasting blood glucose levels on day 6 and day 11 after adenoviral injection.
(C) Insulin tolerance test on day 11.
(D) Glucose tolerance test on day 8.
(E) Serum levels of insulin at various time points after glucose challenge on day 8.
(F) Pyruvate tolerance test on day 6 after adenoviral treatment. Note that the data from age-matched db/+ lean littermates are also presented in (B)–(F) for
the purpose of comparison.
Error bars are ±SEM. *p < 0.05; **p < 0.01 versus db/db +luc group (n = 5–6).Hepatic Overexpression of APPL1 Alleviates
Hyperglycemia and Insulin Resistance in Obese Mice
To further confirm the insulin-sensitizing effects of APPL1 in an
in vivo setting, we evaluated the metabolic changes in db/db
obese mice with frank diabetes following adenovirus-mediated
APPL1 overexpression. The ectopic expression of APPL1 in
the liver tissue of these mice was detectable at day 3, and was
still present at day 16 after initial injection (Figure 4A). As
expected, infusion of adenovirus via tail vein injection did not
affect APPL1 expression in any other tissues examined,
including muscle and adipose tissue (data not shown).
OverexpressionofAPPL1 in the livercausedasignificantamelio-
ration of both fasting and fed hyperglycemia in db/db diabeticmice, restoring themtonearly normal valuesobserved in lean litter-
mates (Figure 4B). Insulin tolerance and glucose tolerance tests
showed that adenovirus-mediated APPL1 overexpression led to
obvious alleviations in both insulin resistance and glucose intoler-
ance in db/db mice, as evidenced by much smaller areas under
the glucose curves compared to those infused with adenovirus
encoding luciferase control (Figures 4C and 4D). In db/db mice
with APPL1 overexpression, circulating insulin levels at both base-
line (16 hr after starvation) and various time points during glucose
challenge were much lower than those in the luciferase control
group (Figure 4E). Pyruvate tolerance test showed that APPL1
overexpression decreased pyruvate-induced gluconeogenesis to
a level close to that observed in lean littermates (Figure 4F).Cell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc. 421
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APPL1, TRB3, and Insulin-Evoked Akt SignalingConsistent with our finding in primary rat hepatocytes, adeno-
virus-mediated APPL1 overexpression significantly increased
Akt phosphorylation at Ser-473 after either insulin or glucose
administration in db/db mice (Figure S2). Glycogen content in
the liver tissue, as determined by both histological and enzy-
matic methods, was significantly elevated by APPL1 overex-
pression (Figures S3A and S3B). By contrast, APPL1 had no
obvious effect on hepatic lipid content, as evaluated by oil red
O staining and biochemical analysis (Figures S3C and S3D).
Adenovirus-mediated overexpression of APPL1 also led to
significant alleviations in insulin resistance and glucose intoler-
ance in high-fat diet-induced obese mice (data not shown).
APPL1 Does Not Affect Insulin-Evoked Signaling
Events Upstream of Akt
Insulin induces Akt activation by stimulating tyrosine phosphor-
ylation of IRS1 and IRS2, which in turn triggers activation of
phosphoinositide-3-kinase (PI3K) and phosphoinositide-depen-
dent kinase 1 (PDK1). We next investigated whether APPL1
regulates these upstream signaling events in the liver tissue of
C57 mice (Figure S4). Although adenovirus-mediated knock-
down of APPL1 impaired insulin-evoked Akt activation in the liver
(Figure 3), it had no obvious effect on either the protein levels or
insulin-elicited tyrosine phosphorylation of IRS1 and IRS2, or on
insulin-induced elevation of PI3K activity (Figures S4A and S4B).
Suppression of APPL1 expression by siRNA did not alter either
the protein abundance or the activity of PDK1 under either basal
condition or 10 min after insulin administration (Figure S4C), or
on its subcellular localization (data not shown). In addition,
knockdown of APPL1 expression did not alter the protein abun-
dance of protein phosphatase 2A (PP2A) or its enzyme activity at
either baseline or 10min after insulin administration (Figure S4D).
Adenovirus-mediated overexpression of APPL1 in the liver of
db/dbmice also had no obvious impact on insulin-induced phos-
phorylation of IRS1 and IRS2, or on the activity of PI3K, PDK1, or
PP2A (data not shown).
APPL1 Blocks the Interaction between Akt and TBR3
Several previous studies have shown a direct interaction of
APPL1 with Akt (Mitsuuchi et al., 1999; Saito et al., 2007; Yang
et al., 2003). It is well established that the activity of Akt can be
modulated via its interaction with various binding partners. In
particular, the pseudokinase tribble 3 (TRB3) binds to Akt and
prevents insulin-mediated Akt phosphorylation by its upstream
kinases (Du et al., 2003; Koo et al., 2004). Interestingly, although
both APPL1 and TRB3 interact with Akt, the two proteins exert
opposite effects on phosphorylation of Akt. We therefore inves-
tigated the effect of APPL1 on the interactions between TRB3
and Akt2, a major isoform responsible for the metabolic actions
of insulin (Cho et al., 2001). Immunoprecipitation analysis de-
tected the association of Akt with both APPL1 and TRB3 under
the basal condition (Figure 5A). Insulin stimulation did not have
obvious effects on the interaction between APPL1 and Akt, but
attenuated the association between Akt and TRB3. Notably,
the association of Akt with TRB3 was markedly enhanced by
knockdown of APPL1 expression, but was suppressed by
APPL1 overexpression (Figure 5B). These findings raise the
possibility that APPL1 potentiates insulin-induced Akt activation
by blocking its association with TRB3.
To address the physiological relevance of the above findings,
we further investigated the interplay between Akt, APPL1, and
TRB3 in mouse livers. Consistent with a previous report (Du
et al., 2003), our western blot analysis showed a much higher
protein level of TRB3 in the liver tissue of db/db mice compared
to that in wild-type littermates, whereas the expression levels of
Akt and APPL1 were comparable between the two groups
(Figure S5A). Interestingly, coimmunoprecipitation analysis de-
tected a significantly elevated association between Akt and
TRB3, and a decreased association between Akt and APPL1 in
the liver tissue of db/db obese mice (Figure S5B). In high-fat
diet-induced obese mice and KK-Ay obese mice, we also
observed an increased association of Akt with TRB3 and
a decreased association of Akt with APPL1 compared to lean
littermates (data not shown). Importantly, overexpression of
APPL1 in the liver of db/db obese mice suppressed the interac-
tion between Akt and TRB3 (Figure S5C).
APPL1 Counteracts the Inhibitory Effects
of TRB3 on Insulin-Induced Akt Signaling
To further elucidate the molecular basis whereby APPL1 inhibits
the interaction between TRB3 and Akt, we established in vitro
pull-down assays using recombinant TRB3 tagged with gluta-
thione S-transferase (GST-TRB3) and APPL1 tagged with six
histidines (His-APPL1) at their NH2 termini. This analysis showed
that endogenous Akt from primary rat hepatocytes bound
robustly to recombinant GST-TRB3 (Figure S6A), but not GST
Figure 5. APPL1 Modulates the Interaction
between Akt and TRB3 in Hepatocytes
(A) Rat hepatocytes were transfected with
a plasmid encoding HA-tagged Akt or an empty
vector for 48 hr, and then treated with 10 nM
insulin for various periods. Cell lysates were
subjected to immunoprecipitation with anti-HA
antibody, and then probed with anti-TRB3, anti-
APPL1, or anti-Akt, as indicated.
(B) Cells were infected with adenovirus encoding
APPL1 or luciferase, or APPL1-specific siRNA
(siAPPL1) or scrambled control as indicated for
6 hr, and subsequently transfected with a plasmid
encoding HA-tagged Akt. Cell lysates harvested at
48 hr after transfection were subjected to immuno-
precipitation and immunoblot analysis as in (A).422 Cell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc.
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APPL1, TRB3, and Insulin-Evoked Akt SignalingFigure 6. APPL1 Antagonizes the Inhibitory Effect of TRB3 on Insulin-Induced Akt Phosphorylation and Suppression of the Gluconeogenic
Program in Primary Rat Hepatocytes
(A) Cells were infected with adenovirus encoding luciferase (adv-luc), TRB3 (adv-TRB3), and/or APPL1 (adv-APPL1) at the concentrations (p.f.u./cell) indicated.
At 36 hr after adenoviral infection, cells were starved for another 12 hr, and stimulated with 10 nM insulin for various periods, as indicated. Cell lysates were
subjected to western blot analysis using anti-TRB3, -APPL1, -phospho-, and -total Akt, as specified.
(B and C) The effects of insulin on cAMP/Dex-induced glucose production and expression of the two gluconeogenic genes were analyzed as in Figure 2. The data
are presented as percentage of inhibition by insulin relative to cells treated with cAMP/Dex alone. Error bars are ±SEM. **p < 0.01 versus the group infected with
adv-luc only; #, p < 0.05; ##, p < 0.01 versus the group infected with adv-TRB3 (25 p.f.u./cell) plus adv-luc (75 p.f.u./cell). n = 5–6 in each group.alone. The binding of Akt to GST-TRB3 was abolished by adeno-
virus-mediated overexpression of APPL1, or by direct addition of
purified recombinant APPL1 into the in vitro reaction mixture.
Conversely, the interaction between Akt and purified His-
APPL1 was largely attenuated by either adenovirus-mediated
overexpression of TRB3 or by incubation with an excessive
amount of recombinant GST-TRB3 (Figure S6B). Consistent
with the results from thepull-down analysis, our gel overlay assay
(far western) further confirmed that TRB3 interacted directly with
Akt preimmobilized on the nitrocellulose membranes, and this
interaction was blocked by coincubation with an excessive
amount of recombinant His-APPL1 (Figure S6C). By contrast, re-
combinant APPL1bound to the immobilizedAkt under bothbasal
and insulin-stimulated conditions, and this interaction was atten-
uatedbyadding an excessive amount of recombinantGST-TRB3
to the incubation buffer (Figure S6D). These results suggest that
APPL1 and TRB3 bind to Akt in a competitive manner.
Wenext investigated the interplay betweenAPPL1andTRB3on
insulin-evokedAktsignaling inprimary rathepatocytes.Consistent
with the previous finding (Du et al., 2003), adenovirus-mediated
overexpression of TRB3 led to a significant reduction in insulin-
evokedphosphorylation of Akt, andattenuated the ability of insulin
to suppress the expression of gluconeogenic genes and glucose
production induced by cAMP/Dex (Figure 6). This inhibitory effect
of TRB3 on insulin-induced Akt phosphorylation and suppression
of thegluconeogenicprogramwasabolishedbyadenovirus-medi-
ated elevation of APPL1 expression in a dose-dependentmanner,
suggesting that APPL1 can directly antagonize the insulin-desen-
sitizing effects of TRB3 on Akt signaling.
APPL1 and TRB3 Exert Opposite Effects
on the Subcellular Distribution of Akt
The diversity and specificity of insulin signal transduction are
accomplished in part by spatial compartmentalization of keysignaling components. Although the plasma membrane is tradi-
tionally thought to be a major site for Akt activation, a growing
body of evidence suggests that trafficking through the endoso-
mal apparatus is also important for achieving full activation of
insulin-evoked Akt signaling (Su et al., 2006). Insulin has been
reported to induce the endosomal localization of Akt as well
as its upstream components such as PI3K (Balbis et al.,
2000). A recent study on zebrafish demonstrates that the poten-
tiating effect of APPL1 on Akt activation occurs within the endo-
somes (Schenck et al., 2008). We therefore investigated the
effects of APPL1 on subcellular distribution of Akt in well-
defined subcellular fractions (cytosol, plasma membrane, and
endosomes) from the liver of C57 mice. Under the fasting condi-
tion, Akt was present predominantly in the cytosol in an inactive
form (Figure 7A). A small portion of Akt was also detectable in
the endosomes, but not in the plasma membrane. APPL1 was
evenly distributed in the cytosol and in the endosomes. Insulin
stimulation induced the translocation of Akt to the plasma
membrane as well as the endosomes. Interestingly, insulin-
induced Akt translocation to the endosomes was accompanied
by increased accumulation of APPL1 in this compartment.
Furthermore, insulin-stimulated Akt translocation to the endo-
somes in mouse livers was markedly elevated by APPL1 overex-
pression (Figure 7B), but decreased by knockdown of APPL1
expression (Figure 7C). Insulin-induced Akt translocation to
the plasma membrane was also reduced by APPL1 knockdown
and was elevated by APPL1 overexpression, whereas the
magnitude of these changes was much smaller than that in
the endosomes.
TRB3was foundexclusively in the cytosolic fraction underboth
basal and insulin-stimulated conditions (Figure 7A). Knockdown
or overexpression of APPL1 had no effect on intracellular locali-
zation of TRB3 (data not shown). Noticeably, overexpression of
TRB3 in the liver tissue of C57 mice blocked insulin-evokedCell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc. 423
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APPL1, TRB3, and Insulin-Evoked Akt Signalingtranslocation of Akt to the endosomes as well as the plasma
membrane (Figure S7).
DISCUSSION
This study provides both ex vivo and in vivo evidence showing
that APPL1 can potentiate the hepatic actions of insulin on
suppressing glucose production through Akt activation. In
primary hepatocytes, insulin-evoked phosphorylation of Akt
and its downstream targets and inhibition of the gluconeogenic
program are markedly attenuated by knockdown of APPL1
expression, but enhanced by its overexpression. The physiolog-
ical relevance of APPL1 as a key regulator of insulin signaling is
also supported by both loss-of-function and gain-of-function
studies in animal models. Most strikingly, selective overexpres-
sion of APPL1 in the liver causes an almost complete reversal
of hyperglycemia, insulin resistance, and glucose intolerance in
Figure 7. APPL1 Promotes Insulin-Evoked Akt Recruitment to
the Endosomes and the Plasma Membrane
(A) Subcellular distribution of Akt, APPL1, and TRB3 in mouse liver under basal
and insulin-stimulated conditions. Mice were fasted overnight, and sacrificed
after receiving a single injection of insulin for 0 or 10 min. Aliquots (40 mg
protein) of the plasma membrane (PM), endosomes (EN), and cytosol purified
from the liver of these mice were subjected to immunoblotting analysis using
various antibodies, as indicated.
(B and C) C57 male mice were injected with adenovirus encoding APPL1
(adv-APPL1) or luciferase (adv-luc), or adenovirus encoding APPL1 siRNA
(siAPPL1) or scrambled control, as indicated. On day 10 after injection, mice
were fasted overnight, received a single injection of insulin, and then sacrificed
to obtain liver tissue for subcellular fractionation as in (A). Aliquots (40 mg
protein) of EN and PM fractions were subjected to western blot analysis using
anti-total Akt.424 Cell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc.db/db obese mice, suggesting that APPL1 might represent
a potential therapeutic target for the treatment and/or prevention
of hepatic insulin resistance and T2DM.
Several recent reports have shown that APPL1 interacts with
and activates Akt (Liu et al., 2002; Saito et al., 2007; Yang
et al., 2003). However, the underlying mechanisms have yet to
be explored. In this study, we demonstrate that APPL1 does
not play a role in modulating insulin-induced signaling events
upstream of Akt. Instead, the potentiating effect of APPL1 on
insulin-induced Akt activation is attributed in part to its ability
in blocking the association of Akt with its endogenous inhibitor
TRB3. In several insulin target tissues including hepatocytes,
myotubes, and endothelium, TRB3 interacts with Akt and
prevents Akt phosphorylation by its upstream kinases (Andreozzi
et al., 2008; Du et al., 2003; Kato andDu, 2007). In addition, TRB3
blocks insulin-stimulated Akt translocation to the plasma
membrane by its direct interaction with Akt (He et al., 2006).
Elevated TRB3 expression has previously been implicated as
a mediator of insulin desensitization in the liver tissue of db/db
obese mice (Du et al., 2003) as well as in several other insulin-
resistant conditions (He et al., 2006; Koo et al., 2004). Noticeably,
hepatic overexpression of TRB3 in amounts comparable to
those in db/db mice promotes hyperglycemia and insulin resis-
tance, whereas knocking down its expression improves insulin
sensitivity in db/db mice (Du et al., 2003). Our present study
shows that APPL1 inhibits the interaction between Akt and
TRB3 in primary hepatocytes as well as in mouse liver tissue,
which is accompanied by increased membrane translocation
and enhanced activation of Akt in response to insulin stimulation.
Both our in vitro pull-down assay and far western analysis
demonstrate that APPL1 directly competes with TRB3 for
binding to Akt. Furthermore, overexpression of APPL1 can
counteract the inhibitory effect of TRB3 on insulin-evoked Akt
activation and suppression of the gluconeogenic program in
rat hepatocytes. These findings suggest that insulin-mediated
Akt activation is finely tuned by the relative expression level of
TRB3 and APPL1, and their binding to this kinase.
Although the protein level of APPL1 remains unchanged in
obese mice with insulin resistance, we observed a significantly
decreased Akt association with APPL1 and an increased Akt
association with TRB3 compared to the lean control mice,
perhaps due to the elevated expression of TRB3. Noticeably,
blockage of the augmented interaction between Akt and TRB3
in the liver of db/db obese mice by hepatic overexpression of
APPL1 is paralleled by a marked alleviation of hyperglycemia
and insulin resistance. These findings raise the possibility that
the imbalance in Akt association with APPL1 and TRB3 may
contribute to hepatic insulin resistance in db/db obese mice.
The antidiabetic actions of APPL1 observed in db/db mice can
be explained in part by its counteracting effect against elevated
inhibition of TRB3 on Akt activation.
Another notable observation of the present study is the ability
of APPL1 to promote insulin-evoked translocation of Akt to the
endosomal compartment. In line with a previous report (Balbis
et al., 2000), our subcellular fraction analysis shows that insulin
stimulates Akt translocation to the plasma membrane as well
as to the endosomes inmouse liver. Furthermore, insulin-evoked
endosomal recruitment of Akt is associated with increased
APPL1 translocation to this compartment. In addition to the
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been implicated as an important site for achieving full Akt activa-
tion by insulin as well as for determining the substrate specificity
of this insulin signaling pathway. The activated insulin receptor
kinase complexes are rapidly internalized into the endosomes
upon insulin stimulation (Fiory et al., 2004). The endosomal
compartment is the important site for IRS1 phosphorylation,
recruitment, and activation of PI3K subunits in adipocytes (Inoue
et al., 1996; Nave et al., 1996). Subcellular fractionation analysis
has demonstrated that insulin-stimulatedmembrane recruitment
of p85 (the regulatory subunit of PI3K) occurs predominantly in
the microsomal fraction enriched with the endosomes, but not
in the plasma membrane fraction (Nave et al., 1996). Noticeably,
a key role of the endosomal compartment in the insulin-evoked
Akt signaling cascade is highlighted by several recent reports
showing that knockdown of the small GTPase Rab5, a major
regulator of endocytosis, blocks insulin-stimulated activation of
Akt as well as glucose uptake in adipocytes (Su et al., 2006;
Huang et al., 2001). APPL1 is a downstream effector protein of
Rab5 (Miaczynska et al., 2004). A large portion of APPL1 is colo-
calized with Rab5 in the endosomal compartment (Miaczynska
et al., 2004). In zebrafish, APPL1-mediated Akt activation occurs
predominantly within the endosomes where some Akt
substrates (such as GSK3) are also available (Schenck et al.,
2008). Consistent with these zebrafish-based observations, the
present study also shows that APPL1-mediated potentiation of
Akt activation by insulin results in a markedly enhanced GSK3b
phosphorylation and increased glycogen accumulation inmouse
liver.
The detailed molecular mechanism by which the interplay
between APPL1 and TRB3 modulates insulin-mediated Akt
activation remains to be determined. Importantly, our results
demonstrate that APPL1 and TRB3 exhibit a distinct pattern of
subcellular distribution and possess opposite effects on the
membrane translocation of Akt. TRB3 is predominantly at the
cytosolic fraction of liver tissue and is virtually undetectable in
the endosome and plasma membrane even after insulin stimula-
tion. Overexpression of TRB3 arrests Akt in the cytosol and
prevents insulin-induced Akt translocation to the endosomes
and the plasma membrane. In contrast to TRB3, insulin stimula-
tion causes the redistribution of APPL1 from the cytosol to the
endosomes as well as the plasma membrane. Furthermore,
APPL1 also promotes insulin-induced Akt translocation from
the cytosol to the endosomes and plasma membrane. Taken in
conjunction, these data suggest that insulin-mediated Akt acti-
vation is finely tuned by APPL1 and TRB3 through spatial regu-
lation. TRB3 inhibits Akt activation by arresting it at the cytosol
and blocking its membrane translocation. By contrast, APPL1
competes with TRB3 for binding to Akt, subsequently promoting
Akt translocation to the cell membrane for further activation.
Besides binding to Akt, APPL1 also interacts with several other
molecules involved in signaling transduction, including both
regulatory (p85) and catalytic (p110) subunits of PI3K (Mitsuuchi
et al., 1999), Rab5, GIPC (Varsano et al., 2006), and inositol
5-phosphatase (Erdmann et al., 2007). In addition, APPL1
possesses phosphoinositide-binding properties (Chial et al.,
2008; Li et al., 2007a). Our present study does not exclude the
possibility that the interactions between APPL1 with these
signaling components also contribute to the potentiating effectsof APPL1 on Akt activation. Further detailed analysis of the
molecular basis underlying the potentiating effects of APPL1
on insulin-evoked activation of the Akt signaling cascade might
shed new light on the fundamental mechanism whereby insulin
controls glucose homeostasis.
EXPERIMENTAL PROCEDURES
Antibodies and Chemicals
Rabbit polyclonal antibodies against total Akt, phospho-Akt (Ser-473), total
GSK3b, phospho-GSK3b (Ser-9), total FOXO1, and phospho-FOXO1 (Ser-
256) were from Cell Signaling Technology, and antibodies against IRS1 and
IRS2, and anti-phosphotyrosine (Tyr[P]) were purchased from Upstate
Biotechnology. Goat anti-Akt2 IgG was from Symansis. Rabbit anti-TRB3
and anti-HA antibodies were from Calbiochem. Insulin, dexamethasone,
cAMP, PP2 (4-amino-5-[4-chlorophenyl]-7-[t-butyl]pyrazolo[3,4-d]pyrimidine)
and PP3 (4-amino-7-phenylpyrazolo[3,4-d]pyrimidine] were from Sigma.
[g-32P]ATP was from Amersham.
Animal Experiments
C57BL/6J male mice and Wistar male rats were purchased from the animal
unit of The University of Hong Kong. Twelve-week-old male C57BL/KsJ-
lepr(db)/lepr(db) obese/diabetic mice and age-matched lean littermate db/+
mice were originally obtained from Jackson Laboratories. The mice were
housed in a room under controlled temperature (23C ± 1C) with free access
to water and standard chow. Glucose tolerance and insulin tolerance tests
were conducted as we previously described (Xu et al., 2005). Serum levels
of insulin were quantified using an ELISA kit from Mercodia AB (Uppsala,
Sweden). Pyruvate tolerance test was performed to estimate gluconeogenesis
as follows. Mice were starved for 16 hr, and then injected intraperitoneally with
pyruvate (2 g/kg) dissolved in saline. Blood glucose levels were determined in
tail blood every 30min for 2 hr using the Ascensia Elite XL blood glucose meter
(Bayer Health Care). All of the experiments were conducted under our institu-
tional guidelines for the humane treatment of laboratory animals.
Construction of Adenoviral Vectors
for Knockdown or Overexpression of APPL1
An adenovirus-mediated small hairpin RNAi delivery system was used to
knock down APPL1 expression. The oligonucleotides against APPL1 and
scrambled control are listed in Table S1. The forward and reverse oligonucle-
otides were annealed, ligated into pENTR/U6 entry vector, and then subcloned
into pAd/BLOCK-iT DEST vector through recombination. To construct adeno-
viral vectors for overexpression of APPL1 or TRB3, cDNA encoding full-length
human APPL1 or TRB3was inserted into pshuttle-CMV vector, and then subcl-
oned into pAdeasy-1 adenoviral backbone vector (Stratagene) through recom-
bination in Escherichia coli.
To package adenovirus, the adenoviral vectors were linearized with the
restriction enzyme PacI and transfected into HEK293 cells using Lipofect-
amine 2000. After several rounds of propagation, recombinant adenovirus
was purified by an AdEasy virus purification kit (Stratagene), and the titer
was determined with an endpoint assay as described (Xu et al., 2005).
Isolation of Primary Rat Hepatocytes, Cell Culture,
and Measurement of Glucose Production
Primary hepatocyteswere prepared frommaleWistar rats (200 g) which have
been fasted for 16 hr as described (Wang et al., 2002). Cells were plated on
collagen type I-coated 12-well plates in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum at a density of 53 105 cells per well, and
then transduced with various adenoviruses for 48 hr. Thereafter, cells were
washed three times with warm PBS to remove glucose, pretreatedwith insulin,
followed by stimulation with cAMP/dexamethasone in glucose-free DMEM
containing gluconeogenic substrates (2 mM sodium pyruvate). Glucose
concentrations were determined with a glucose assay kit from Sigma.
Subcellular Fractionation
Rat primary hepatocytes grown in 35 mm culture dishes (1.5 3 106) were
rinsed with ice-cold PBS, and dissolved with a lysis buffer containing 20 mMCell Metabolism 9, 417–427, May 6, 2009 ª2009 Elsevier Inc. 425
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2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4,
and protease inhibitor cocktails (Roche, Mannheim, Germany). Cytoplasmic
and nuclear fractions were prepared using NE-PER nuclear and cytoplasmic
extraction reagents according to the manufacturer’s instruction (Pierce).
C57 mice fasted overnight were anesthetized and killed at various times
after insulin injection. Livers were rapidly excised, minced in an ice-cold buffer
consisting of 250 mM sucrose, 4 mM imidazole (pH 7.4) plus protease inhibitor
cocktails and phosphatase inhibitors (2 mM sodium fluoride and 1 mM sodium
orthovanadate), and homogenized using a teflon pestle. The cytosol, plasma
membrane, and endosomal fractions were isolated from the liver homoge-
nates using discontinuous sucrose-gradient ultracentrifugation as described
previously (Balbis et al., 2000; Khan et al., 1989).
Immunoprecipitation and Immunoblotting
Immunoprecipitation was conducted as described previously (Cheng et al.,
2007). Proteins from total cell lysates, various subcellular fractions, or immuno-
precipitated complexes were separated by SDS-PAGE, and probed with
different primary antibodies as specified in each figure legend. The specific
signals were amplified by addition of horseradish peroxidase-conjugated
secondary antibodies and visualized using an enhanced chemiluminescence
system (Amersham). The intensity of the protein bands was quantified using
an image processor program (ImageJ).
Hepatic Glycogen and Triglyceride Contents
The cryostat sections of mouse livers obtained after 6 hr of fasting were depar-
affinized by incubating with xylene for 5 min, hydrated, and then oxidized in
0.5% periodic acid solution for 5 min. After washing with distilled water, the
sections were incubated with periodic acid Schiff (Sigma) prior to imaging.
The glycogen concentrations in liver were also quantified using an enzymatic
method as follows. Frozen liver tissue (20–30 mg) was dissolved in 1 M NaOH
at 65C for 1 hr, spotted onto Whatman 3M paper, dried, and washed three
times with 65% ethanol. The samples were then digested with amyloglucosi-
dase at 45C for 4 hr and glucose content was measured with a glucose
oxidase assay. Oil red O staining of lipid droplets in liver sections and enzy-
matic quantification of hepatic triglyceride contents in the liver tissue were
performed as described (Xu et al., 2005).
RNA Extraction and Real-Time PCR
Total RNA from rat hepatocytes or mouse liver tissue was purified with a Trizol
reagent (Invitrogen), and treated with RNase-free DNase (Promega) at 37C for
30 min to remove genomic DNA. For reverse transcription, 1 mg of the total
RNA was converted to first-strand complementary DNA in 20 ml reactions using
acDNAsynthesiskit (Promega).Quantitative real-timePCRformRNAexpression
of the two gluconeogenic genes was performed in duplicate in a total reaction
volume of 20 ml with a fluorescent TaqMan 50-nuclease assay on an Applied Bio-
systemsPrism7000sequencedetectionsystem (assay ID:Mm00440636_m1 for
PEPCK and Mm00839363_m1 for G6Pase). Analysis was performed with ABI
Prism 7000 SDS software and normalized against 18S RNA.
Statistical Analysis
Experiments were performed routinely with four to six mice per group with
values presented as means ± standard error. Statistical significance was
determined by one-way ANOVA or Student’s t test. In all statistical compari-
sons, p value < 0.05 was used to indicate a significant difference.
SUPPLEMENTAL DATA
Supplemental data include Supplemental Experimental Procedures, one
table, and seven figures and can be found with this article online at http://
www.cell.com/cell-metabolism/supplemental/S1550-4131(09)00091-6.
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